Can HBsAg Be Non-Reactive in Chronic Hepatitis B?
Yes, HBsAg can become non-reactive in persons with chronic hepatitis B after spontaneous or treatment-induced HBsAg loss, entering what is termed the "HBsAg-negative phase." 1, 2
The HBsAg-Negative Phase of Chronic HBV Infection
According to EASL guidelines, the natural history of chronic HBV infection includes a fifth phase specifically designated as the "HBsAg-negative phase" that occurs after HBsAg loss 1. This is a well-recognized clinical entity with the following characteristics:
Key Features:
- HBsAg becomes undetectable in serum (non-reactive on standard testing)
- Low-level HBV replication may persist with detectable HBV DNA in the liver tissue 1, 2
- Serum HBV DNA is generally undetectable, though may be detected at very low levels (<200 IU/ml) 1
- Anti-HBc antibodies remain detectable with or without anti-HBs 1, 2
- This represents "occult HBV infection" when HBV DNA is detectable in liver tissue despite negative HBsAg 1
Clinical Significance and Outcomes:
HBsAg loss before cirrhosis develops is associated with improved outcomes, including reduced risk of cirrhosis, decompensation, and hepatocellular carcinoma 1, 2. The spontaneous rate of HBsAg loss in inactive carriers is 1-3% per year, typically occurring after several years of persistently undetectable HBV DNA 1.
Critical Caveat - Risk of Reactivation:
Immunosuppression can lead to HBV reactivation in HBsAg-negative patients 1, 2. This is a crucial clinical pitfall: patients who have cleared HBsAg but harbor occult infection remain at risk for viral reactivation when receiving immunosuppressive therapy, chemotherapy, or biologic agents.
Important Distinction:
If cirrhosis developed before HBsAg loss, patients remain at risk for hepatocellular carcinoma and other complications despite HBsAg seronegativity 1. These patients require continued surveillance.
Resolved Hepatitis B vs. Occult Infection:
The 2007 AASLD guidelines define "resolved hepatitis B" as having previous history of acute or chronic hepatitis B (or presence of anti-HBc/anti-HBs), HBsAg negative, undetectable serum HBV DNA, and normal ALT levels 3. However, even in "resolved" infection, HBV DNA may be detectable in liver tissue by PCR in up to half of patients 4.
Clinical Implications:
- Always check anti-HBc status in patients being considered for immunosuppression, even if HBsAg is negative
- Monitor for reactivation in HBsAg-negative/anti-HBc-positive patients receiving immunosuppressive therapy
- Continue HCC surveillance if cirrhosis was present before HBsAg loss
- Recognize that HBsAg negativity does not always mean complete viral eradication—occult infection with intrahepatic HBV DNA persistence is common
The clinical relevance of occult HBV infection in the absence of immunosuppression remains unclear 1, but the potential for reactivation makes identification of these patients essential in appropriate clinical contexts.